Press Releases May 19, 2026 04:10 PM

RxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology Forum

RxSight to Present at Stifel 2026 Virtual Ophthalmology Forum Detailing Innovations in Post-Surgical Vision Customization

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
RXST

RxSight, Inc., a NASDAQ-listed ophthalmic medical device company specializing in adjustable intraocular lenses for cataract surgery, announced its participation in the upcoming Stifel 2026 Virtual Ophthalmology Forum. The company’s management will engage in a fireside chat to discuss their Light Adjustable Lens technology and company developments.

RxSight, Inc. to Present at the Stifel 2026 Virtual Ophthalmology Forum
RXST
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • RxSight will present at the Stifel 2026 Virtual Ophthalmology Forum on May 26, 2026.
  • The company’s Light Adjustable Lens (LAL) is unique as it allows post-surgical adjustments to improve vision outcomes after cataract surgery.
  • The presentation can increase awareness among investors and ophthalmology professionals about RxSight's innovative IOL technology.

ALISO VIEJO, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., today announced plans to participate in the upcoming Stifel 2026 Virtual Ophthalmology Forum. Management is scheduled to participate in a fireside chat on Tuesday, May 26, 2026, at 10:00 a.m. Pacific Time. A live and archived webcast of the presentation will be available on the company’s investor relations website at https://investors.rxsight.com/.

About RxSight, Inc.

RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®, collectively the “LAL”), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.

Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
omoravcevic@rxsight.com


Risks

  • Market adoption risk: The success of the Light Adjustable Lens depends on physician and patient adoption rates within the ophthalmology sector.
  • Regulatory and competitive risks: The medical device industry is subject to regulatory oversight and competition from other IOL providers, which may affect RxSight’s market share.
  • Technological risks: Advances by competitors or technological challenges in the LAL system could affect future sales and company performance.

More from Press Releases

Diana Shipping Inc. Alerts Genco Shareholders of Institutional Shareholder Services’ Recommendation to Vote Against Genco Shipping & Trading's Poison Pill Jun 9, 2026 Mingteng International Corporation Inc. Announces Pricing of $2.26 Million Registered Direct Offering Jun 9, 2026 Toll Brothers Announces Model Home Grand Opening at Santa Rita Ranch in Liberty Hill, Texas Jun 9, 2026 Toll Brothers Announces Final Opportunity to Own a New Luxury Home at Toll Brothers at Skye Canyon - Paloma Collection in Las Vegas, Nevada Jun 9, 2026 CORRECTION Jun 9, 2026